Equfina 50 mg

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease

Trial Timeline

Jun 3, 2021 → Mar 20, 2025

About Equfina 50 mg

Equfina 50 mg is a pre-clinical stage product being developed by Eisai for Parkinson Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05225324. Target conditions include Parkinson Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05225324Pre-clinicalCompleted

Competing Products

20 competing products in Parkinson Disease

See all competitors
ProductCompanyStageHype Score
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
LY4006896 + PlaceboEli LillyPhase 1
36
ATH-1017 + PlaceboLeonaBioPhase 2
17
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
Mirabegron + PlaceboAstellas PharmaApproved
43
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
EqufinaEisaiPre-clinical
26
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
Safinamide MesilateEisaiApproved
43
E2007 + E2007 + E2007EisaiPhase 2
35
E2007EisaiPhase 2
35